ALSO READRoche drug cocktail doubles chance of holding lung cancer at bay Roche win boosts case for adding chemo to cancer immunotherapy Novartis' skin cancer drug posts win in trials, Roche flops Roche's new breast cancer drug that could cut treatment time denied patent Biocon withdraws applications to sell two cancer drugs in Europe
Roche would pay $27 per share for Ignyta, representing a premium of about 74 percent to the stock's closing price on Thursday, they said.
Ignyta will continue its operations in San Diego and will be responsible for the ongoing pivotal study of entrectinib, its most advanced drug.
The US company has a suite of drugs in early stage development that use gene therapy to kill off the underlying diseases that drive cancer tumor growth.
Reuters reported on Thursday Ignyta was in advanced talks to sell itself, just three years after the company went public with focus on precision drugs and diagnostics.
The deal is expected to close in the first half of 2018, the companies said.
Sidley Austin LLP and Latham & Watkins LLP were legal counsel to Roche and Ignyta, respectively.